N/A N=230 Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=449 Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement — 8.69 percentage of participants
Phase 2 N=142 ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Solid Tumor · Lymphoma · Peripheral T-Cell Lymphoma
Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…
Phase 2 N=1,066 An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Phase 3 N=347 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Phase 2 N=13 A Study of AK-01 (LY3295668) in Solid Tumors
Neoplasms · Neoplasm Metastasis · Triple Negative Breast Neoplasms
Primary: Phase 1: Maximum Tolerated Dose — 25 milligram (mg)
N/A N=161 Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
N/A N=62 Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
Phase 1 N=304 A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Tumors Characterized by Genetic Abnormalities of ALK
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=42 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Phase 2 N=6 AUY922 for Advanced ALK-positive NSCLC
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
Phase 1 N=40 Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
ALK-activated Tumors
Primary: Incidence Rate of Dose Limiting Toxicities (DLTs) Occurring During First Cycle of Treatment — 0; 0; 0; 1 Participants
Phase 2 N=118 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Hepatoblastoma · Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Number of Participants With Overall Response — 0; 1; 0; 0 Patients
Phase 1 N=26 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 2 N=33 A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Brain Neoplasms
Primary: Establish a Safe Dose for Oral 5-ALA Administration — 0; 0; 0; 0 Dose Limiting Toxicity
Phase 2 N=16 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1 — 0 percentage of patients
N/A N=3,800 Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
Cancer
Primary: Number of Patients With ALT (Alanine Transaminase) >=3x (Times) Upper Limit of Normal (ULN) — 11 participants
Phase 1 N=5 TIL Therapy for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
Phase 2 N=72 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Myxofibrosarcoma · Recurrent Adult Soft Tissue Sarcoma · Recurrent Leiomyosarcoma
Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…
Phase 1 N=26 Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Progressive Metastatic Malignancies
Primary: The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies — 0; 2; 4 Events
Phase 3 N=271 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Phase 2 N=124 LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Phase 2 N=7 IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
FIGO Stage III and IV Ovarian Cancer · FIGO Stage III and IV Fallopian Tube Cancer · FIGO Stage III Primary Peritoneal Cancer
Primary: Progression Free Survival — 50; 100 Percentage of PFS
Phase 2 N=24 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Phase 3 N=275 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Non-small Cell Lung Cancer · Lung Cancer · Advanced Malignancies
Primary: Progression-free Survival (PFS) — 24.016; 11.072; 16.821 months — p=<0.0001
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=140 LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants
Phase 2 N=87 A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
Adenoid Cystic Carcinoma
Primary: Overall Response Rate (ORR) — 3; 2 Participants
Phase 3 N=376 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) — 16.6; 8.1 Months — p=<0.001
Phase 2 N=21 Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients